Andrew Sewell
Physician-researcher affiliated with Yale School of Medicine and the VA Connecticut Healthcare System
Data updated
Papers
Trials
Research Footprint
Andrew Sewell appears in 8 tracked papers (2006–2024), most studied alongside Psilocybin, LSD and Salvia Divinorum, across Headache Disorders (Cluster & Migraine), Chronic Pain and Safety & Risk Management.
Most-cited paper: Response of cluster headache to psilocybin and LSD (259 citations).
Frequent co-authors: Deepak Cyril D’Souza, Brian Pittman and Emmanuelle Schindler.
Background & Research
R. Andrew Sewell was a physician-scientist who published influential work on psychedelic compounds, especially their potential effects on cluster headache and migraine. His papers appear in collaborations with Yale researchers and the VA Connecticut Healthcare System, and later work notes his death and dedicates publications to his memory. He is also associated with earlier clinical research on cannabis and neuropsychiatry.
Key Impact
He was a key early clinical researcher on psychedelics and headache disorders, including psilocybin and LSD studies in cluster headache and migraine.
Collaboration Network
8 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Andrew Sewell is associated with.
VA Connecticut Healthcare System
governmentThe VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.
View stakeholder →Mclean Hospital
Harvard Medical School-affiliated psychiatric hospital and one of the leading mental health research institutions in the United States. Operates a dedicated Ketamine Service for treatment-resistant depression and is actively expanding into psilocybin research for depression, bipolar disorder, and other psychiatric conditions.
View stakeholder →